Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded Evaluator, No-treatment Control, Multicenter, Prospective Clinical Study of RHA® Redensity Eye for the Treatment of Moderate to Severe Tissue Volume Deficiencies in the Infraorbital Regions

NCT04577898 is registered in ClinicalTrials.gov with Teoxane SA as lead sponsor.

NCT NCT04577898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04577898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded Evaluator, No-treatment Control, Multicenter, Prospective Clinical Study of RHA® Redensity Eye for the Treatment of Moderate to Severe Tissue Volume Deficiencies in the Infraorbital Regions
Lead sponsor
Teoxane SA
Phase
Not applicable
Overall status
Completed
Start date
December 2, 2020
Completion date
February 14, 2025
Enrollment
248 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

infra-orbital hollows, tear-trough deformity, wrinkle